Jubilant Pharmova Reports Robust FY26 Growth Driven by CDMO Sterile Injectables Expansion
Strong Financial Performance Jubilant Pharmova reported a 14 percent year-on-year revenue increase to Rs 8,280 crore for the financial year 2025-26, fueled by significant expansion in its CDMO Sterile Injectables, Allergy Immunotherapy, and Generics divisions. The company announced an 8 percent rise in EBITDA to Rs 1,326 crore and a 7 percent increase in normalized…